Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate

Chronic inflammation is a risk factor for the onset of cancer and the regular use of aspirin reduces the risk of cancer development. Here we showed that therapeutic dosages of aspirin counteract the pro-tumorigenic effects of the inflammatory cytokine interleukin(IL)-6 in cancer and non-cancer cell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Brighenti, Elisa, Giannone, Ferdinando Antonino, Fornari, Francesca, Onofrillo, Carmine, Govoni, Marzia, Montanaro, Lorenzo, Treré, Davide, Derenzini, Massimo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5325359/
https://ncbi.nlm.nih.gov/pubmed/27557515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11441
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak